Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01129674 · ClinicalTrials.gov registry record · Phase 2
A Long-Term, Open-Label, Study on Schizophrenia
A Phase 2 study, sponsored by Eli Lilly and Company.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1,210
- Enrollment target
NCT01129674 is a Phase 2 study that was terminated before completion, run by Eli Lilly and Company. The registered enrollment target is 1,210 participants.
The verdict
NCT01129674, a Phase 2 study, was terminated before completion, sponsored by Eli Lilly and Company.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1,210 participants
- Enrollment target
Study Summary
The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.
Interventions
- DRUG Risperidone
- DRUG Olanzapine
- DRUG Quetiapine
- DRUG Aripiprazole
- DRUG LY2140023
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,210 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01129674
The ClinicalTrials.gov registry entry for NCT01129674 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1,210 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Risperidone is the first listed.
NCT01129674 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01129674 about?
NCT01129674 is a clinical study titled "A Long-Term, Open-Label, Study on Schizophrenia". The primary purpose of the study is to help answer the following research questions: How LY 2140023 can be tolerated by patients with Schizophrenia compared to standard of care treatment in 52 weeks time period. Whether LY 2140023 can help patients with Schizophrenia.
What is the current status of trial NCT01129674?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1,210 participants. The study started on 2010-06. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01129674?
The interventions under investigation include: Risperidone (DRUG), Olanzapine (DRUG), Quetiapine (DRUG), Aripiprazole (DRUG), LY2140023 (DRUG).
Who is sponsoring clinical trial NCT01129674?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.